Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972812 | 1.00 | FFAR4 (0.36) | FFAR4GRIN1GRIN2BKMT2ACHRM4 | |
| SCHEMBL3399328 | 0.93 | CHRNA7 (0.35) | FFAR4GRIN1GRIN2BKMT2ACHRM4 | |
| SCHEMBL314941 | 0.93 | CHRNA7 (0.35) | FFAR4GRIN1GRIN2BKMT2ACHRM4 | |
| SCHEMBL2141918 | 0.87 | HRH3 (0.35) | — | |
| SCHEMBL4859819 | 0.87 | CHRM4 (0.33) | CHRM4CHRNA7 | |
| SCHEMBL2141911 | 0.87 | HRH3 (0.35) | — | |
| SCHEMBL314907 | 0.87 | CHRNB2 (0.32) | — | |
| SCHEMBL4864102 | 0.87 | GRIN1 (0.34) | GRIN1GRIN2BCHRM4P2RY14 | |
| SCHEMBL314906 | 0.87 | CHRNB2 (0.32) | — | |
| SCHEMBL4864112 | 0.87 | GRIN1 (0.34) | GRIN1GRIN2BCHRM4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668021-B1 | NOVEL THIOXYLOSE COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF IN THERAPEUTICS | FOURNIER LAB SA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-7470671-B2 | Thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics | LABORATOIRE FOURNIER (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | NOTUM, STS, AGPS | FFAR4 1898/4885GRIN1 4518/4885GRIN2B 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.